FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2564026979> ?p ?o ?g. }

• W2564026979 endingPage "8003" @default.
• W2564026979 startingPage "8003" @default.
• W2564026979 abstract "8003 Background: We have shown that first-line HDT leads to an improved EFS and OS over CHOP in adults with aggressive NHL (NEJM 2004) and that adding R to the HDT was feasible and might improve the results (BBMT 2010). We present the preliminary analysis of a multicenter RCT comparing R-CHOP14 to R-HDT in adults with DLBCL (clinical trial.gov: NCT 00561379). Methods: Pts 18 to 60 y.o. CD20 + DLBCL AA stage 1-2 with bulk ≥ 7 cm or 3 -4 were rdz at dg (stratified on aaIPI) between R-CHOP14 (8 courses if response after the first 4) and R-HDT. This consisted of 2 courses of HD CHOP-like, 15 days apart, with R (375/mg/m2) on day 1 of each, then R on d 22, harvest of G-CSF mobilized PBSC on d 28, 29, R on d 36 followed by HD methotrexate with cytarabin. For pts who achieved a response after these 3 courses, BEAM started on d 66 to 80 followed by PBSCT. In each arm, the interm response was assessed by CT Scan and PET (Cheson criteria JCO 2007). Pts not achieving a PR or a neg PET had a salvage Tx and auto PBSCT. Results: 340 pts included 01/2005 to 06/2010, 286 pts evaluable at time of abstract, 143 in each arm. Characteristics of the pts in the 2 arms are super imposable. Overall 56% bulk, 72% >2 AA stage and 58% aa IPI>1. The Rdz tx was completed in 67% in the R-CHOP arm and 53% in the R-HDT arm. The interm evaluation showed the same rate of response with CT scan (CR + CRu: 65% and 62% following 4 x R-CHOP14 and first 3 courses of R-HDT). PET remained more often pos after the first 3 courses of R-HDT (41% vs 28%; p=0.03). Of the 98 pts with pos interm PET, 84 had a salvage of which 62 underwent auto PBSCT. On ITT the ORR (CR + Cru) was 82% and 76% in the R-CHOP and R-HDT arms respectively (p=0.8). With a med FU of 25 m, the 3y OS is 83%. No difference according to the tx arm in any of the aaIPI strata. The 3y PFS and DFS are 76% and 83%, no difference according to the tx arm. The 3 y OS and DFS for pts in R-CHOP arm and in R-HDT arm acc to interm PET are shown in the table. Conclusions: R-CHOP14 is as efficient, less toxic, and spares resources as compared to this R-HDT program. Salvage based on interm PET is not harmful and provides excellent results. PET neg PET pos R-CHOP 3y OS/DFS 88% / 80% 84% / 82% R-HDT 3y OS/DFS 80% /92% 86% / 89%" @default.
• W2564026979 created "2017-01-06" @default.
• W2564026979 creator A5000473136 @default.
• W2564026979 creator A5007933887 @default.
• W2564026979 creator A5017050164 @default.
• W2564026979 creator A5019790026 @default.
• W2564026979 creator A5019961853 @default.
• W2564026979 creator A5031977714 @default.
• W2564026979 creator A5044137685 @default.
• W2564026979 creator A5049306115 @default.
• W2564026979 creator A5058751095 @default.
• W2564026979 creator A5059170424 @default.
• W2564026979 creator A5062422990 @default.
• W2564026979 creator A5068144072 @default.
• W2564026979 creator A5072749507 @default.
• W2564026979 creator A5077435007 @default.
• W2564026979 creator A5079890028 @default.
• W2564026979 creator A5082764126 @default.
• W2564026979 creator A5083266654 @default.
• W2564026979 creator A5088580473 @default.
• W2564026979 date "2011-05-20" @default.
• W2564026979 modified "2023-09-27" @default.
• W2564026979 title "First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: Preliminary results of the GOELAMS 075 prospective multicenter randomized trial." @default.
• W2564026979 doi "https://doi.org/10.1200/jco.2011.29.15_suppl.8003" @default.
• W2564026979 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28023030" @default.
• W2564026979 hasPublicationYear "2011" @default.
• W2564026979 type Work @default.
• W2564026979 sameAs 2564026979 @default.
• W2564026979 citedByCount "29" @default.
• W2564026979 countsByYear W25640269792012 @default.
• W2564026979 countsByYear W25640269792013 @default.
• W2564026979 countsByYear W25640269792014 @default.
• W2564026979 countsByYear W25640269792015 @default.
• W2564026979 countsByYear W25640269792016 @default.
• W2564026979 countsByYear W25640269792017 @default.
• W2564026979 countsByYear W25640269792018 @default.
• W2564026979 countsByYear W25640269792019 @default.
• W2564026979 countsByYear W25640269792020 @default.
• W2564026979 countsByYear W25640269792021 @default.
• W2564026979 countsByYear W25640269792023 @default.
• W2564026979 crossrefType "journal-article" @default.
• W2564026979 hasAuthorship W2564026979A5000473136 @default.
• W2564026979 hasAuthorship W2564026979A5007933887 @default.
• W2564026979 hasAuthorship W2564026979A5017050164 @default.
• W2564026979 hasAuthorship W2564026979A5019790026 @default.
• W2564026979 hasAuthorship W2564026979A5019961853 @default.
• W2564026979 hasAuthorship W2564026979A5031977714 @default.
• W2564026979 hasAuthorship W2564026979A5044137685 @default.
• W2564026979 hasAuthorship W2564026979A5049306115 @default.
• W2564026979 hasAuthorship W2564026979A5058751095 @default.
• W2564026979 hasAuthorship W2564026979A5059170424 @default.
• W2564026979 hasAuthorship W2564026979A5062422990 @default.
• W2564026979 hasAuthorship W2564026979A5068144072 @default.
• W2564026979 hasAuthorship W2564026979A5072749507 @default.
• W2564026979 hasAuthorship W2564026979A5077435007 @default.
• W2564026979 hasAuthorship W2564026979A5079890028 @default.
• W2564026979 hasAuthorship W2564026979A5082764126 @default.
• W2564026979 hasAuthorship W2564026979A5083266654 @default.
• W2564026979 hasAuthorship W2564026979A5088580473 @default.
• W2564026979 hasConcept C126322002 @default.
• W2564026979 hasConcept C141071460 @default.
• W2564026979 hasConcept C2778559949 @default.
• W2564026979 hasConcept C2779338263 @default.
• W2564026979 hasConcept C2780653079 @default.
• W2564026979 hasConcept C2989005 @default.
• W2564026979 hasConcept C71924100 @default.
• W2564026979 hasConcept C90924648 @default.
• W2564026979 hasConceptScore W2564026979C126322002 @default.
• W2564026979 hasConceptScore W2564026979C141071460 @default.
• W2564026979 hasConceptScore W2564026979C2778559949 @default.
• W2564026979 hasConceptScore W2564026979C2779338263 @default.
• W2564026979 hasConceptScore W2564026979C2780653079 @default.
• W2564026979 hasConceptScore W2564026979C2989005 @default.
• W2564026979 hasConceptScore W2564026979C71924100 @default.
• W2564026979 hasConceptScore W2564026979C90924648 @default.
• W2564026979 hasIssue "15_suppl" @default.
• W2564026979 hasLocation W25640269791 @default.
• W2564026979 hasOpenAccess W2564026979 @default.
• W2564026979 hasPrimaryLocation W25640269791 @default.
• W2564026979 hasRelatedWork W1996279342 @default.
• W2564026979 hasRelatedWork W2012238656 @default.
• W2564026979 hasRelatedWork W2020184844 @default.
• W2564026979 hasRelatedWork W2031558687 @default.
• W2564026979 hasRelatedWork W2096661684 @default.
• W2564026979 hasRelatedWork W2096774443 @default.
• W2564026979 hasRelatedWork W2344519974 @default.
• W2564026979 hasRelatedWork W2899250601 @default.
• W2564026979 hasRelatedWork W3031222282 @default.
• W2564026979 hasRelatedWork W3031860663 @default.
• W2564026979 hasVolume "29" @default.
• W2564026979 isParatext "false" @default.
• W2564026979 isRetracted "false" @default.
• W2564026979 magId "2564026979" @default.
• W2564026979 workType "article" @default.